Cargando…

The use of and adherence to CTCAE v3.0 in cancer clinical trial publications

BACKGROUND: The Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) was released in 2003, and has been widely used as the predominant set of toxicity criteria for cancer clinical trials and scientific meetings. However, the degree to which the elements of CTCAE v3.0 are followed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Sheng, Chen, Qiang, Wang, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323176/ https://www.ncbi.nlm.nih.gov/pubmed/27564109 http://dx.doi.org/10.18632/oncotarget.11576

Ejemplares similares

Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE(®) to Provide Two Distinct and Complementary Perspectives
por: Minasian, Lori M, et al.
Publicado: (2022)

A toolbox of different approaches to analyze and present PRO-CTCAE data in oncology studies
por: Regnault, Antoine, et al.
Publicado: (2023)

Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period
por: Lee, M. K., et al.
Publicado: (2023)

Efficacy of the PRO-CTCAE mobile application for improving patient participation in symptom management during cancer treatment: a randomized controlled trial
por: Lee, Mangyeong, et al.
Publicado: (2023)

Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer
por: Kowalchuk, Roman O., et al.
Publicado: (2021)

From Chicago classification v3.0 to v4.0: Diagnostic changes and clinical implications
por: Sallette, Morgane, et al.
Publicado: (2022)

Development of a keyword library for capturing PRO-CTCAE-focused “symptom talk” in oncology conversations
por: Durieux, Brigitte N, et al.
Publicado: (2023)

THU513 Are Endocrinologists Using CTCAE Grading System For Endocrine Side Effects Of Cancer Treatment With Immune Checkpoint Inhibitors?
por: Arnouk, Nelly, et al.
Publicado: (2023)

CCIE security v3.0 quick reference
por: Lobo, Lancy, et al.
Publicado: (2011)

CCIE Voice v3.0 quick references
por: Lewis, Mark
Publicado: (2012)

BRAD V3.0: an upgraded Brassicaceae database
por: Chen, Haixu, et al.
Publicado: (2021)

Veterinary Cooperative Oncology Group—Common Terminology Criteria for Adverse Events (VCOG‐CTCAE v2) following investigational therapy in dogs and cats
por: LeBlanc, Amy K., et al.
Publicado: (2021)

Marketing 3.0 /
por: Kotler, Philip
Publicado: (2018)

Delphi 3.0
por: Charte Ojeda, Francisco
Publicado: (1998)

Talent 3.0
por: Díaz-Llairó, Amparo
Publicado: (2017)

Manager 3.0
por: Karsh, Brad
Publicado: (2013)

Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®)
por: Caminiti, Caterina, et al.
Publicado: (2022)

Perceptions of Public Health 3.0: Concordance Between Public Health Agency Leaders and Employees
por: Balio, Casey P., et al.
Publicado: (2019)

Selecting a PRO-CTCAE-based subset for patient-reported symptom monitoring in prostate cancer patients: a modified Delphi procedure
por: Feldman, E., et al.
Publicado: (2023)

Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers
por: Günther, Maximilian, et al.
Publicado: (2023)

A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy
por: Christiansen, Mille Guldager, et al.
Publicado: (2023)

iPath3.0: interactive pathways explorer v3
por: Darzi, Youssef, et al.
Publicado: (2018)

CCIE security v3.0 configuration practice labs
por: Bhaiji, Fahim Hussain Yusuf
Publicado: (2010)

SIGNOR 3.0, the SIGnaling network open resource 3.0: 2022 update
por: Lo Surdo, Prisca, et al.
Publicado: (2022)

3.0T MR-CAD: Clinical Value in Diagnosis of Breast Tumor Compared with Conventional MRI
por: Liu, Yu-Hui, et al.
Publicado: (2014)

PINA 3.0: mining cancer interactome
por: Du, Yang, et al.
Publicado: (2020)

QS version 3.0
por: Chang, Yih-Long
Publicado: (1995)

Visual Foxpro 3.0
por: Tiznado Santana, Marco Antonio
Publicado: (1996)

Expert f♯ 3.0
por: Syme, Don, et al.
Publicado: (2012)

Programming F# 3.0
por: Smith, Chris
Publicado: (2012)

Release of MARYLIE 3.0
por: Dragt, A J, et al.
Publicado: (1999)

C# 3.0 Cookbook
por: Hilyard, Jay, et al.
Publicado: (2008)

Customer Experience 3.0
por: Goodman, John
Publicado: (2014)

EcoGene 3.0
por: Zhou, Jindan, et al.
Publicado: (2013)

Editorial: Sexuality 3.0
por: Eleuteri, Stefano, et al.
Publicado: (2023)

Adherence to and Dropout from Liraglutide 3.0 mg Obesity Treatment in a Real-World Setting
por: Ko, Hae-Jin, et al.
Publicado: (2022)

Routine Surveillance of Chemotherapy Toxicities in Cancer Patients Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
por: Wang, Tian Qi, et al.
Publicado: (2018)

Windows 3.0 : guia de autoenseñanza
por: Weiskamp, Keith
Publicado: (1992)

The utility of ADC parameters in the diagnosis of clinically significant prostate cancer by 3.0-Tesla diffusion-weighted magnetic resonance imaging
por: Kus, Aylin Altan
Publicado: (2021)

Health Informatics in the Public Health 3.0 Era: Intelligence for the Chief Health Strategists
por: DeSalvo, Karen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jmi43kmsgutcr1id4bra13be9p